PMID- 36312630
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221102
IS  - 2168-8184 (Print)
IS  - 2168-8184 (Electronic)
IS  - 2168-8184 (Linking)
VI  - 14
IP  - 9
DP  - 2022 Sep
TI  - Importance of Insulin Resistance in the COVID-19 Era: A Retrospective Analysis of 
      a Single Center in Mexico.
PG  - e29542
LID - 10.7759/cureus.29542 [doi]
LID - e29542
AB  - Introduction and objectives Type 2 diabetes mellitus (T2DM) has been one of the 
      main risk factors associated with mortality from the coronavirus disease 2019 
      (COVID-19). Insulin resistance (IR) is a preceding and underlying condition of 
      T2DM, which has been thought that it could increase mortality from COVID-19 since 
      it favors the entry of severe acute respiratory syndrome coronavirus type 2 in 
      the host cell. This article reports a biochemical study that estimated the 
      prevalence of IR in COVID-19 patients and non-diabetic patients without COVID-19 
      history. It also assesses the prognostic role of IR in the evolution of patients 
      with COVID-19. Materials and methods In this single-center, retrospective and 
      cross-sectional design, we included patients with severe and critical COVID-19 
      and non-diabetic patients without COVID-19 history. We calculated the Homeostatic 
      Model Assessment Insulin Resistance (HOMA-IR) and defined IR with a HOMA-IR >2.6. 
      We estimated the prevalence of IR in both groups and used x (2) to assess the 
      association between IR and mortality from severe and critical COVID-19. Results 
      One hundred and twenty-three COVID-19 patients were included with a mean age of 
      53+/-15 years: 77 (62.6%) were men and 46 (37.4%) were women. Eighty (65%) patients 
      were critical while the rest were severe. Forty-three (35%) patients died. 
      Seventy-one (57.7%) patients had IR; there was no evidence of an association 
      between IR and mortality from severe or critical COVID-19. Fifty-five 
      non-diabetic patients without COVID-19 history were included with a median age of 
      40 (26-60) years; 35 (63.6%) were men and 20 (36.4%) were women. Nineteen (34.5%) 
      people had IR. Conclusion IR was more prevalent in patients with severe and 
      critical COVID-19 than in non-diabetic patients without COVID-19 history. Our 
      results showed no evidence of the association between IR and mortality from 
      severe and critical COVID-19.
CI  - Copyright (c) 2022, Peralta Amaro et al.
FAU - Peralta Amaro, Ana L
AU  - Peralta Amaro AL
AD  - Internal Medicine, Hospital de Especialidades Dr. Antonio Fraga Mouret, Instituto 
      Mexicano del Seguro Social, Mexico City, MEX.
FAU - Ramirez Ventura, Julio C
AU  - Ramirez Ventura JC
AD  - Internal Medicine, Hospital de Especialidades Dr. Antonio Fraga Mouret, Instituto 
      Mexicano del Seguro Social, Mexico City, MEX.
FAU - Banuelos Garcia, Luis R
AU  - Banuelos Garcia LR
AD  - Internal Medicine, Hospital de Especialidades Dr. Antonio Fraga Mouret, Instituto 
      Mexicano del Seguro Social, Mexico City, MEX.
FAU - Pecero Garcia, Emily I
AU  - Pecero Garcia EI
AD  - Internal Medicine, Hospital de Especialidades Dr. Antonio Fraga Mouret, Instituto 
      Mexicano del Seguro Social, Mexico City, MEX.
FAU - Valadez Calderon, Jose G
AU  - Valadez Calderon JG
AD  - Internal Medicine, Hospital de Especialidades Dr. Antonio Fraga Mouret, Instituto 
      Mexicano del Seguro Social, Mexico City, MEX.
FAU - Hernandez Flandes, Rosa N
AU  - Hernandez Flandes RN
AD  - Endocrinology and Diabetes, Hospital de Especialidades Dr. Antonio Fraga Mouret, 
      Instituto Mexicano del Seguro Social, Mexico City, MEX.
LA  - eng
PT  - Journal Article
DEP - 20220924
PL  - United States
TA  - Cureus
JT  - Cureus
JID - 101596737
PMC - PMC9595245
OTO - NOTNLM
OT  - covid-19
OT  - covid-19 retro
OT  - glucose
OT  - homa-ir
OT  - insulin resistance
OT  - mortality
COIS- The authors have declared that no competing interests exist.
EDAT- 2022/11/01 06:00
MHDA- 2022/11/01 06:01
PMCR- 2022/09/24
CRDT- 2022/10/31 04:42
PHST- 2022/09/24 00:00 [accepted]
PHST- 2022/10/31 04:42 [entrez]
PHST- 2022/11/01 06:00 [pubmed]
PHST- 2022/11/01 06:01 [medline]
PHST- 2022/09/24 00:00 [pmc-release]
AID - 10.7759/cureus.29542 [doi]
PST - epublish
SO  - Cureus. 2022 Sep 24;14(9):e29542. doi: 10.7759/cureus.29542. eCollection 2022 
      Sep.